ascopubs.org

Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.

Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies. This is an ASCO Meeting Abstract from the ...
ascopubs.org

Comparative survival outcomes of non-clear cell and clear cell renal cell carcinomas with indications for adjuvant pembrolizumab.

First line treatment of pancreatic metastases in metastatic renal cell carcinoma: Insights from the UK Renal Oncology Collaborative (UK ROC)—Tyrosine kinase inhibitors time to shine? This is an ASCO ...
CURE

FDA Fast Tracks ITM-94 For Clear Cell Renal Cell Carcinoma Diagnosis

The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The ...
Targeted Oncology

FDA Fast Tracks PET Diagnostic Agent for Clear Cell Renal Cell Carcinoma

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...
The New England Journal of Medicine

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of ...
CURE

Understanding the Role of Nutrition in Kidney Cancer Care

At the 2025 International Kidney Cancer Symposium, Dr. Michael Staehler, of the University of Munich, highlighted the ...